Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals

🇨🇳 CNBC (CN) —
Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals

AI Summary

Chinese biopharma stocks recorded gains as the U.S. considers permitting continued drug licensing deals with Chinese firms. This potential regulatory flexibility has boosted investor sentiment towards Chinese pharmaceutical companies.

Chinese biopharma stocks rose on Monday after a report that the U.S. may continue to allow most drug licensing deals with Chinese firms.

Politics Markets Deals Health Chinese biopharma U.S. regulations drug licensing stocks investor sentiment

Read original source →